Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest iBio Inc. Stories

2013-10-28 08:29:30

NEWARK, Del., Oct. 28, 2013 /PRNewswire/ -- iBio, Inc. ( NYSE MKT: IBIO ) today announced receipt on October 25, 2013 of notice from NYSE Regulation that iBio had resolved all previously cited continued listing deficiency with respect to listing standards of the NYSE MKT LLC's (the "Exchange") Company Guide, and therefore continues its listing eligibility, subject, as is the case for all listed issuers, to assessment on an ongoing basis by the Exchange. (Logo:...

2013-10-15 20:20:57

NEWARK, Del., Oct. 15, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that it is providing holders of its warrants to purchase common stock issued on January 13, 2012 (the "2012 Warrants") the opportunity to exercise the 2012 Warrants at a reduced exercise price for a limited period. (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) From October 15, 2013 until 5:00 p.m. on November 12, 2013 (the "Expiration Time"), a holder of 2012 Warrants may...

2013-10-14 08:24:47

NEWARK, Del., Oct. 14, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that on October 11, 2013, the NYSE MKT (the "Exchange") notified the Company that it accepted the Company's updated Plan of Compliance and granted the Company an extension until December 2, 2013 to regain compliance with the continued listing standards set forth in Sections1003(a)(ii), 1003(a)(iii), and 1003(a)(iv) of the NYSE MKT Company Guide. (Logo:...

2013-10-07 16:25:21

NEWARK, Del., Oct. 7, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), a biotechnology company focused on commercializing its proprietary transformative recombinant platform technology for development and production of biologics using transient gene expression in unmodified green plants, today confirmed, as required by Section 610(b) of the NYSE MKT Company Guide, the receipt of an audit opinion for its year ended June 30, 2013, containing a going concern qualification. This...

2013-08-13 08:30:46

NEWARK, Del., Aug. 13, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today that the US Patent and Trademark Office has allowed patent application 13/243,796 entitled "System for Expression of Genes in Plants." This invention is a part of iBio's patented iBioLaunch(TM) technology platform that causes common green plants to produce commercial quantities of targeted human proteins in proper form for use as active pharmaceutical ingredients and enables nuanced control of the...

2013-08-05 08:28:36

NEWARK, Del., Aug. 5, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today that the US Patent and Trademark Office has allowed patent application 13/445,492 entitled "Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides." The fundamental composition of matter and method claims allowed grant important exclusivity over new, modified carrier molecules derived from iBio's proprietary iBioModulator system and their use with one or more...

2013-06-24 08:29:07

NEWARK, Del., June 24, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today released the following information, which was contained in the Portuguese language report published on June 18, 2013 in the official Journal of the Government of Brazil under the heading, "Brazil Expands Production of Biological Medicines." This information is being released in this translated form by iBio to assure uniform distribution to the public of material information regarding iBio. References...

2013-06-10 08:29:34

NEWARK, Del., June 10, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that its patent covering the composition and production of a human monoclonal antibody for the treatment of anthrax infection has been allowed in China. This patent, which will issue from Chinese patent application No.:200680036136.1, is entitled "COMPOSITIONS AND METHODS FOR PRODUCTION OF IMMUNOGLOBULINS." (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) The claims of the allowed patent...

2013-06-05 08:28:28

NEWARK, Del., June 5, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that on May 31, 2013, the NYSE MKT (the "Exchange") notified the Company that it accepted the Company's Plan of Compliance and granted the Company an extension until October 14, 2013 to regain compliance with the continued listing requirements of the Exchange. On April 18, 2013, the Company received notice from NYSE MKT Staff indicating that the Company was below certain of the Exchange's continued listing...

2013-05-29 08:30:36

NEWARK, Del., May 29, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that a patent to increase influenza vaccine performance through the use of iBio's proprietary iBioModulator fusion protein technology has been allowed in China. The patent, which will issue from Chinese patent application No.: 200780008098.3, will further broaden the territories in which patent exclusivity has been secured for this novel technology. In the U.S., the technology is covered by issued U.S....